Skip to main content
Clinical Trials/NCT01675362
NCT01675362
Completed
Phase 4

A Randomized Controlled Trial for Evaluating Protective Effects of Antioxidants (Selenium and Vitamins A, C and E), Calcium Channel Blocker (Verapamil) and Angiotensin Receptor Blocker (Losartan) Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury

Mansoura University1 site in 1 country160 target enrollmentAugust 2012

Overview

Phase
Phase 4
Intervention
Placebo
Conditions
Kidney Calculi
Sponsor
Mansoura University
Enrollment
160
Locations
1
Primary Endpoint
Renal damage
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

This study will be conducted to evaluate the protective effects and mechanisms of antioxidants (vitamins A, C, E and Selenium), calcium channel blocker (Verapamil) and angiotensin receptor blocker (Lozartan) against shock wave induced renal injuries.

Detailed Description

The protective effect will be evaluated via estimation of the changes in renal tubular enzyme (NGAL) and detection of albumen levels in urine. The mechanisms of protection will be investigated by estimation of renal perfusion and functional changes using dynamic MRI.

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
October 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ahmed R. EL-Nahas

Assistant Professor of Urology

Mansoura University

Eligibility Criteria

Inclusion Criteria

  • Well functioning kidney (serum creatinine \<1.2 mg/dl).
  • Solitary renal stone.
  • Size: 25 mm or less in the largest diameter.

Exclusion Criteria

  • Contraindications to ESWL
  • Previous surgical treatment of renal stones.
  • Congenital renal anomalies.
  • Pediatric patients (age \<18 years).
  • Patients with Diabetes or hypertension

Arms & Interventions

Control group

They will receive placebo

Intervention: Placebo

Antioxidant group

They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week

Intervention: Antioxidant group

Calcium channel Blockers

They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week

Intervention: Calcium Channel Blockers

Angiotensin receptor blocker group

They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week

Intervention: Angiotensin receptor blocker group

Outcomes

Primary Outcomes

Renal damage

Time Frame: two hours and one week after Extracorporeal shock wave lithotripsy (ESWL)

The protective effect will be evaluated via estimation of the changes in renal tubular enzyme (NGAL) and detection of albumen levels in urine.

Secondary Outcomes

  • The mechanisms of renal protection(Before ESWL, 2 hours and 1 week after ESWL)

Study Sites (1)

Loading locations...

Similar Trials